Beone Medicines LTD. (BEIGF) — 8-K Filings

8-K Filings (26)

• 8-K Filing — Dec 19, 2025
• 8-K Filing — Dec 18, 2025
• BeOne Medicines Ltd. Enters Material Definitive Agreement — Nov 19, 2025 Risk: medium
  On November 13, 2025, BeOne Medicines Ltd. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as
• BeOne Medicines Ltd. Files 8-K on Financials — Aug 29, 2025 Risk: low
  BeOne Medicines Ltd. filed an 8-K on August 29, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibi
• BeOne Medicines Ltd. Enters Material Definitive Agreement — Aug 25, 2025 Risk: medium
  BeOne Medicines Ltd. announced on August 25, 2025, that it entered into a material definitive agreement. This filing also indicates the creation of a direct fin
• BeiGene, Ltd. Files 8-K on Security Holder Vote Matters — May 21, 2025 Risk: low
  On May 21, 2025, BeiGene, Ltd. filed an 8-K report to announce the submission of matters to a vote of its security holders. The filing does not disclose specifi
• BeiGene Reports Unregistered Equity Sales — May 13, 2025 Risk: medium
  On May 13, 2025, BeiGene, Ltd. filed an 8-K report detailing unregistered sales of equity securities. The filing indicates that the company has engaged in trans
• BeiGene, Ltd. Files 8-K — Apr 29, 2025 Risk: low
  BeiGene, Ltd. filed an 8-K on April 29, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial d
• BeiGene, Ltd. Files 8-K on Financials — Apr 28, 2025 Risk: low
  BeiGene, Ltd. filed an 8-K on April 28, 2025, to report on its results of operations and financial condition. The filing includes financial statements and exhib
• BeiGene Files 8-K for Regulatory and Exhibit Disclosures — Jan 13, 2025 Risk: low
  BeiGene, Ltd. filed an 8-K on January 13, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing does not con
• BeiGene Files 8-K: Other Events & Exhibits — Dec 23, 2024 Risk: low
  BeiGene, Ltd. filed an 8-K on December 23, 2024, reporting other events and financial statements/exhibits. The filing does not contain specific financial figure
• BeiGene, Ltd. Files 8-K for Material Agreement — Dec 10, 2024 Risk: medium
  On December 9, 2024, BeiGene, Ltd. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an
• BeiGene, Ltd. Files 8-K — Nov 19, 2024 Risk: low
  BeiGene, Ltd. filed an 8-K on November 19, 2024, reporting an event that occurred on November 14, 2024. The filing pertains to "Other Events" and "Financial Sta
• BeiGene, Ltd. Files 8-K with Financials and Exhibits — Nov 14, 2024 Risk: low
  On November 14, 2024, BeiGene, Ltd. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosur
• BeiGene, Ltd. Files 8-K Report — Oct 28, 2024 Risk: low
  On October 25, 2024, BeiGene, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific f
• BeiGene, Ltd. Files 8-K on Sept 30, 2024 — Sep 30, 2024 Risk: low
  BeiGene, Ltd. filed an 8-K on September 30, 2024, reporting other events and financial statements. The filing details the company's corporate information, inclu
• BeiGene Announces Board and Officer Changes — Sep 26, 2024 Risk: low
  On September 25, 2024, BeiGene, Ltd. filed an 8-K report detailing changes in its board of directors and executive officers. The filing includes information reg
• BeiGene, Ltd. Files 8-K on Operations and Financials — Aug 29, 2024 Risk: low
  On August 29, 2024, BeiGene, Ltd. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as fin
• BeiGene Announces Board Changes and Officer Compensation Details — Jul 18, 2024 Risk: low
  On July 17, 2024, BeiGene, Ltd. announced changes to its Board of Directors, including the appointment of Dr. Xiaodong Wang as a Class II Director and the resig
• BeiGene Announces Executive Changes and Shareholder Votes — Jun 5, 2024 Risk: medium
  On June 5, 2024, BeiGene, Ltd. filed an 8-K report detailing several key events. The company announced the departure of Director Robert J. H. Smith and the appo
• BeiGene, Ltd. Files 8-K on Financials — Apr 26, 2024 Risk: low
  BeiGene, Ltd. filed an 8-K on April 26, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhib
• BeiGene, Ltd. Files 8-K with Financial Statements — Apr 23, 2024 Risk: low
  On April 23, 2024, BeiGene, Ltd. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating it's an update or disclosure r
• BeiGene Appoints New CMO and CFO — Mar 20, 2024 Risk: medium
  On March 19, 2024, BeiGene, Ltd. announced the appointment of Dr. Xiaojun Wang as Chief Medical Officer and Dr. Yong (Ben) Huang as Chief Financial Officer. The
• BeiGene, Ltd. Files 8-K Report — Mar 15, 2024 Risk: low
  On March 14, 2024, BeiGene, Ltd. filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific fina
• BeiGene, Ltd. Files 8-K Report — Mar 8, 2024 Risk: low
  On March 8, 2024, BeiGene, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or
• BeiGene 8-K Signals Officer/Director Changes, Comp Arrangements — Jan 23, 2024
  BeiGene, Ltd. filed an 8-K on January 23, 2024, reporting an event that occurred on January 22, 2024. This filing indicates changes related to the 'Departure of

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX